Patient Case – Treatment Considerations for ALK+ NSCLC

EP: 1.Brief Overview & Key Insights: Current Treatment Practices for ALK+ NSCLC

EP: 2.Expert Perspectives on Navigating Biomarker Testing for NSCLC Patients

EP: 3.From Results to Therapy: Preparing Patients for ALK Inhibitor Therapy

EP: 4.Key Considerations for First-Line ALK Inhibitor Treatment Selection

EP: 5.Clinical Perspectives on Managing ALK Inhibitor Adverse Events

Now Viewing

EP: 6.Patient Case – Treatment Considerations for ALK+ NSCLC

EP: 7.Monitoring Strategies for ALK Inhibitor Therapy

EP: 8.Patient Education for Long-Term Success on ALK Inhibitor Therapy

EP: 9.Treatment Transitions in ALK+ NSCLC

EP: 10.Long-Term Care in ALK+ NSCLC

EP: 11.Practice Pearls & Resources for ALK+ NSCLC

This segment continues the discussion of a patient with brain metastases and ALK-positive non–small cell lung cancer (NSCLC). The panel analyzes how central nervous system (CNS) involvement, lifestyle needs, and tolerability profiles influence first-line drug selection. Lorlatinib may be prioritized for its CNS activity, but adverse effects may not be acceptable for all patients.

If brain metastases were absent, alectinib could be a better choice due to its milder adverse effect profile. The discussion reveals the complexity of decision-making in real-world settings, where data must be balanced with patient-specific goals and concerns.

Panelists emphasize that individualizing therapy is critical to optimizing outcomes. Even among ALK inhibitors, nuances in efficacy and toxicity require personalized approaches. Ongoing communication between patients and providers ensures alignment on expectations and treatment strategies.